← Leaderboards
David W Kimberlin
University Of Alabama At Birmingham
$10,865,588
Attributed
$10,865,588
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.1M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,463,834 · 21
By mechanism
U54$15,213,995 · 8
U19$2,410,342 · 1
M01$839,497 · 12
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jianguo Gu$14,706,393
- Ralph R Weichselbaum$16,065,057
- Richard J. Whitley$15,110,969
- Michael J Mugavero$16,567,288
- Christina A Muzny$5,578,242
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCongenital InfectionFutureRare DiseasesUnited States National Institutes Of HealthPerinatal InfectionFundingNeonateEnrollmentAntiviral AgentsInfectionInfantCytomegalovirusViralCongenital CytomegalovirusSafetySimplexvirusOralLaboratoriesChildHearingEnterovirusNeonatalDose
Grant awards (54)
Virologic and Immunologic Sample Acquisition Core$2,410,342
U19 · FY2024 · AI · contact PI
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)$1,408,997
U54 · FY2024 · AI · contact PI
EV Sepsis Natural History$316,426
U54 · FY2024 · AI · contact PI
Longitudinal CMV$294,177
U54 · FY2024 · AI · contact PI
Valacyclovir Phase I Trial$227,501
U54 · FY2024 · AI · contact PI
Letermovir Phase I Trial$216,619
U54 · FY2024 · AI · contact PI
Administrative Core$204,551
U54 · FY2024 · AI · contact PI
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)$1,376,828
U54 · FY2023 · AI · contact PI
Administrative Core$712,559
U54 · FY2023 · AI · contact PI
Longitudinal CMV$529,615
U54 · FY2023 · AI · contact PI
EV Sepsis Natural History$255,751
U54 · FY2023 · AI · contact PI
Letermovir Phase I Trial$233,370
U54 · FY2023 · AI · contact PI
Valacyclovir Phase I Trial$207,632
U54 · FY2023 · AI · contact PI
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)$1,372,969
U54 · FY2021 · AI · contact PI
Longitudinal CMV$273,362
U54 · FY2021 · AI · contact PI
EV Sepsis Natural History$258,919
U54 · FY2021 · AI · contact PI
Valacyclovir Phase I Trial$225,859
U54 · FY2021 · AI · contact PI
Letermovir Phase I Trial$191,564
U54 · FY2021 · AI · contact PI
Project-002$150,260
U54 · FY2021 · AI · contact PI
Administrative Core$104,287
U54 · FY2021 · AI · contact PI
Project-001$6,717
U54 · FY2021 · AI · contact PI
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)$1,383,894
U54 · FY2020 · AI · contact PI
Longitudinal CMV$375,626
U54 · FY2020 · AI · contact PI
EV Sepsis Natural History$293,653
U54 · FY2020 · AI · contact PI
Valacyclovir Phase I Trial$261,190
U54 · FY2020 · AI · contact PI
Letermovir Phase I Trial$170,912
U54 · FY2020 · AI · contact PI
Administrative Core$141,237
U54 · FY2020 · AI · contact PI
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)$2,055,558
U54 · FY2019 · AI · contact PI
Administrative Core$719,393
U54 · FY2019 · AI · contact PI
EV Sepsis Natural History$390,492
U54 · FY2019 · AI · contact PI
Longitudinal CMV$308,173
U54 · FY2019 · AI · contact PI
Valacyclovir Phase I Trial$290,830
U54 · FY2019 · AI · contact PI
Letermovir Phase I Trial$255,074
U54 · FY2019 · AI · contact PI
ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX$3,321
M01 · FY2007 · RR · contact PI
BABY FLU TREATMENT$2,215
M01 · FY2007 · RR · contact PI
ORAL VALGANCICLOVIR IN NEONATES WITH SYMPTOMATIC CONGENTIAL CYTOMEGALOVIRUS (CMV$1,661
M01 · FY2007 · RR · contact PI
CLINICAL TRIALS OF THERAPIES FOR HERPES VIRUS$1,384
M01 · FY2007 · RR · contact PI
ORAL VALGANCICLOVIR IN NEONATES WITH SYMPTOMATIC CONGENTIAL CYTOMEGALOVIRUS (CMV$43,711
M01 · FY2006 · RR · contact PI
ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX$4,230
M01 · FY2006 · RR · contact PI
CLINICAL TRIALS OF THERAPIES FOR HERPES VIRUS$3,760
M01 · FY2006 · RR · contact PI
ORAL VALGANCICLOVIR IN NEONATES WITH SYMPTOMATIC CONGENTIAL CYTOMEGALOVIRUS(CMV)$11,742
M01 · FY2005 · RR
ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX$2,248
M01 · FY2005 · RR
CLINICAL TRIALS OF THERAPIES FOR HERPES VIRUS$749
M01 · FY2005 · RR
DOUBLE-BLIND, PLACEBO-CONTROLLED, VIROLOGIC EFFICACY TRIAL OF PLECONARIL$519
M01 · FY2005 · RR
Oral Valganciclovir in Neonates with Congenital CMV$1,937
M01 · FY2004 · RR
Phase III Eval. of Suppressive Therapy with Acyclovir$1,384
M01 · FY2004 · RR
Assessment of subjects who received DHPG to evaluate CMV$554
M01 · FY2004 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL HERPES SIMPLEX$175,256
M01 · FY2002 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL CMNV IN HSV$175,256
M01 · FY2002 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL CMNV IN HSV$175,256
M01 · FY2001 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL HERPES SIMPLEX$175,256
M01 · FY2001 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL CMNV IN HSV$29,529
M01 · FY2000 · RR
IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL HERPES SIMPLEX$29,529
M01 · FY2000 · RR
VIROLOGIC EFFICACY TRIAL OF PLECONARIL (VP63843) IN NEONATES WITH VIRAL MENINGITI$0
M01 · FY2000 · RR